Hormone medicines
Bromocriptine
A dopamine agonist used in several distinct clinical settings; the formulation and diagnosis determine which evidence applies.
Randomized quick-release diabetes trial plus product-specific labels; checked 2026-10-01
Also known as: Parlodel · Cycloset
Practical use
Clinical purpose, evidence and review questions
- Keep the diagnosis attached
- Bring the reason for testing, repeat laboratory results and relevant symptoms to review.
- Record the exact product
- List all dopamine-active and blood-pressure medicines, including the formulation.
- Track effects beyond a number
- Note fainting, daytime sleepiness, nausea and new behavioral changes.
Overview
Bromocriptine activates dopamine D2 receptors. Parlodel is used for specified hyperprolactinemia-related conditions, acromegaly and Parkinson disease. The quick-release Cycloset formulation has a separate US type 2 diabetes indication. A shared ingredient does not make these treatment goals interchangeable.
Risks and limitations
Nausea, dizziness, low standing blood pressure, fainting and sleepiness are important. Compulsive gambling, spending or sexual urges and hallucinations can occur. Fibrotic complications have been reported with some exposures. Pregnancy, postpartum care and blood-pressure medicines require specific clinical review.
How to read this
An elevated prolactin result needs an explanation; it is not by itself a reason to copy a diabetes or Parkinson regimen. Symptom response and the underlying diagnosis matter alongside laboratory changes.
Research explained
Cycloset Safety Trial
Who was studied
3,095 adults with type 2 diabetes randomized 2:1 to quick-release bromocriptine or placebo alongside usual diabetes care for 52 weeks; efficacy and safety analyses used the treated study population.
What was found
Serious adverse events occurred in 8.6% versus 9.6%. A prespecified cardiovascular composite occurred in 1.8% versus 3.2%, with hazard ratio 0.60 (95% CI 0.35–0.96). Nausea was the most common adverse event.
What it cannot establish
The cardiovascular analysis had few events and a specific composite. It does not establish the same benefit for other formulations, indications or people without diabetes.
Read the original studyPreserve the formulation in a claim
The diabetes study tested quick-release bromocriptine, not every product containing the molecule.
Supporting sourceBehavioral changes are clinically relevant
New compulsive urges may not feel like a side effect to the person experiencing them. A family member’s observation can be useful in the medication review.
Supporting sourceClaims versus findings
Not established
Lowering prolactin automatically improves performance or libido.
The selected clinical indications and diabetes trial do not establish that outcome in healthy users.
Check the evidenceCommon questions
Is a 40% relative reduction a 40-percentage-point difference?
No. The reported event proportions differed by 1.4 percentage points, and the hazard ratio describes time-to-event risk.
SourceSources
US prescribing information; checked October 1, 2026
Additional product-specific source
Sources checked 2026-10-01.
General education; not a personal treatment plan.